USE OF AN ANTIBODY WHICH BINDS TO CD20 IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHEUMATOID ARTHRITIS IN A PATIENT WITH AN INADEQUATE RESPONSE TO A TNF- ALPHA INHIBITOR

摘要

The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNF-α inhibitor.